Noven Appoints Executive Director of Clinical Research/Regulatory Affairs

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the appointment of Anthony S. de Padova, M.D. to the newly-created position of Executive Director, Clinical Research/Regulatory Affairs, reporting to Robert C. Strauss, Noven's President and Chief Executive Officer. In this role, Dr. de Padova will be the Company's senior-most medical officer, and will be responsible for the supervision and direction of all medical, regulatory and clinical affairs relating to Noven's existing and developmental products.

``We are very pleased that Dr. de Padova has joined Noven, and the timing couldn't be better,'' said Robert Strauss, Noven's President and Chief Executive Officer. ``As a senior medical officer for four multinational pharmaceutical companies, Tony designed, organized and supervised a range of large-scale clinical programs during his 18-year professional career. Right now, we are beginning Phase III clinical trials for our MethyPatch™ transdermal methylphenidate delivery system for Attention Deficit Hyperactivity Disorder, and have clinical trials for two other products underway. We expect that Tony's experience, insight and leadership will help speed these and our many other R&D projects to market.''

Before joining Noven, Dr. de Padova was Director of Clinical Trials for the School of Medicine, State University of New York at Stony Brook (SUNY), where he was responsible for all research activities, including regulatory oversight, contracts and business development. Prior to SUNY, he served Knoll Pharmaceutical Company as Vice President - Medical Affairs/Clinical Research, and managed a $25 million annual medical affairs and clinical research budget. Earlier, he served Warner Lambert Pharmaceuticals, G.D. Searle Pharmaceuticals, and Ciba-Geigy Pharmaceuticals in various senior supervisory capacities relating to medical and clinical affairs. Dr. de Padova holds patents describing an innovative therapy for treating premenstrual syndrome and pain associated with premenstrual disorders, and has authored or co-authored 11 published articles.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery systems and technologies. Noven has developed and presently manufactures a series of leading-edge products, including the world's smallest estrogen transdermal delivery system, the United States' only combination estrogen/progestin transdermal delivery system, and the first transmucosal patch approved for marketing by the U.S. Food and Drug Administration. With a wide range of additional products in development, Noven is committed to becoming the world's premier developer, manufacturer, and marketer of transdermal and transmucosal drug delivery systems. For additional information on Noven, visit www.noven.com.

Forward looking statements contained in this release are qualified by and subject to the risks and uncertainties specified by Noven in its most recent filings with the Securities and Exchange Commission, including the risk that some or all of Noven's products in development may not receive the approvals necessary to commence marketing.